Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
4/7/21	G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
4/2/21	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1/21	G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
3/25/21	G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
3/5/21	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/3/21	G1 Therapeutics to Participate in Two Investor Conferences in March
3/2/21	G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
2/24/21	G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
2/17/21	G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
2/12/21	FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression